Stimulating brain recovery after stroke using theranostic albumin

nanocarriers loaded with nerve growth factor in combination therapy by Feczkó, Tivadar et al.
First revision 
1 
 
Stimulating brain recovery after stroke using theranostic albumin 
nanocarriers loaded with nerve growth factor in combination 
therapy 
 
Tivadar Feczkó1,2,3, Albrecht Piiper1, Saema Ansar4, Frank W Blixt4, Mukul Ashtikar5, 
Susanne Schiffmann5, Thomas Ulshöfer5, Michael J. Parnham5, Yifat Harel6, Liron 
Limor Israel6, Jean-Paul Lellouche6, Matthias G. Wacker5,7* 
 
1: Department of Medicine 1, University Hospital Frankfurt, Frankfurt, Germany 
2: Institute of Materials and Environmental Chemistry, Research Centre for Natural 
Sciences, Hungarian Academy of Sciences, Budapest, Hungary 
3: Research Institute of Biomolecular and Chemical Engineering, University of 
Pannonia, Veszprém, Hungary 
4: Department of Clinical Sciences, Lund University, Lund, Sweden 
5: Fraunhofer Institute for Molecular Biology and Applied Ecology, Translational 
Medicine and Pharmacology, Frankfurt/Main 
6: Department of Chemistry, Bar Ilan University, Israel 
7: Institute of Pharmaceutical Technology, Goethe University, Frankfurt/Main 
 
 
*Corresponding author 
Dr. Matthias G. Wacker 
Pharmaceutical Technology and Nanosciences 
Fraunhofer-Institute for Molecular Biology and Applied Ecology (IME) 
Translational Medicine and Pharmacology (TMP) 
Building N230, Room 2.03 
Max-von-Laue-Straße 9, D-60438 Frankfurt/Main 
Phone  +49 69 798 - 296 91   
Fax    +49 69 798 - 296 94 
www.ime.fraunhofer.de 
 
  
*Revised Manuscript - include embeded figures/tables and also seperate figures/tables
Click here to view linked References
First revision 
2 
 
Abstract 
For many years, delivering drug molecules across the blood brain barrier has been a 
major challenge. The neuropeptide nerve growth factor is involved in the regulation of 
growth and differentiation of cholinergic neurons and holds great potential in the 
treatment of stroke. However, as with many other compounds, the biomolecule is not 
able to enter the central nervous system. In the present study, nerve growth factor and 
ultra-small particles of iron oxide were co-encapsulated into a chemically crosslinked 
albumin nanocarrier matrix which was modified on the surface with apolipoprotein E. 
These biodegradable nanoparticles with a size of 212 ± 1 nm exhibited monodisperse 
size distribution and low toxicity. They delivered NGF through an artificial blood brain 
barrier and were able to induce neurite outgrowth in PC12 cells in vitro. In an animal 
model of stroke, the infarct size was significantly reduced compared to the vehicle 
control. The combination therapy of NGF and the small-molecular MEK inhibitor U0126 
showed a slight but not significant difference compared to U0126 alone. However, 
further in vivo evidence suggests the hypothesis that successful delivery of the 
neuropeptide is possible as well as the synergism between those two treatments. 
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Abbreviations 
ApoE3   Apolipoprotein E3 
BBB    blood brain barrier 
CAN    cerium ammonium nitrate 
DCM    dichloromethane 
DMSO   dimethyl sulfoxide 
EDC    1-ethyl-3(3-dimethylaminopropyl) carbodiimide 
ERK    Extracellular signal-regulated kinase 
HSA    human serum albumin 
MALHEX-NH-PEG-NHS Maleinimidohexanoic-ω-NHS PEG 
MEK    mitogen-activated protein kinase kinase 
mPEG-SPA-5000  Succinimidyl propionic acid PEG NHS  
MRI    magnetic resonance imaging 
NGF    nerve growth factor 
NHS    N- hydroxysuccinimide 
PAR    passive avoidance reflex 
PBCA    poly(butyl cyanoacrylate) 
PBS    phosphate buffered saline 
PDI    polydispersity index 
PEG    polyethylene glycol 
PVA    polyvinyl alcohol 
SEM    scanning electron microscope 
TEM    transmission electron microscopy 
USPIO   ultra-small superparamagnetic iron oxide  
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1. Introduction 
As one of the most important neuropeptides, nerve growth factor (NGF) is involved in 
the regulation of growth and differentiation of cholinergic neurons [1]. Further, it plays 
a major role in cell survival after ischemic stroke which is a leading cause of death 
globally [2]. A significant reduction of delayed neuronal death was observed after the 
administration of NGF into the cerebral ventricle of rats [3] and even some early clinical 
evidence highlights a beneficial effect on recovery of hypoxic-ischemic brain injuries 
and cerebral perfusion [4, 5]. 
 
Despite the great potential in the treatment of stroke, NGF is not able to pass the blood-
brain barrier (BBB) which makes clinical administration dependent on invasive 
neurosurgical procedures [6, 7]. The BBB is created by the cerebral endothelial cells 
forming tight junctions and sealing the paracellular pathway into the brain [8]. As a 
consequence, the composition of the extracellular fluid within the central nervous 
system (CNS) can be precisely controlled [8]. The endothelial tissue exhibits polarized 
expression of transport proteins [8]. Some of these transporters were addressed using 
nanocarrier systems modified on their surface with targeting moieties such as 
transferrin [9], insulin [10] or the apolipoproteins (Apo) E and A-1 [11, 12]. Poly(butyl 
cyanoacrylate) (PBCA) nanoparticles coated with polysorbate 80 effectively delivered 
NGF to the CNS in an animal model of Alzheimer’s disease [13].  
This coating leads to an adsorption of Apo A-1, B, and E [14]. Kreuter and co-workers 
confirmed an active endocytotic uptake mechanism of ApoE-conjugated albumin 
nanoparticles in vitro [15] and in vivo [12]. In this context, the low density lipoprotein 
receptor (LRP1) was held responsible for the uptake [15]. Human serum albumin 
(HSA) is the most abundant blood protein and has been used as a carrier material for 
a number of therapeutic agents such as survivin miRNA plasmid [16], polo-like kinase 
[17], doxorubicin [18, 19] or paclitaxel [20]. 
 
Exploring the biodistribution of nanocarriers is an important requirement for clinical 
translation of nanocarrier delivery. In this context, ultra-small superparamagnetic 
particles of iron oxide (USPIO) were encapsulated into HSA nanoparticles serving as 
contrast agents for magnetic resonance (MR) imaging [21, 22]. A novel species of 
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maghemite core particles was used [23-25]. The resulting diagnostic HSA nanocarriers 
were successfully tested in vivo [21]. 
 
In the present study, advanced theranostic nanocarriers for the treatment of stroke 
were synthesized by co-desolvation of NGF and HSA in the presence of cerium 
ammonium nitrate (CAN)-stabilized USPIO. The surface of resulting nanocarriers was 
functionalized using apolipoprotein E to facilitate an active transport into the brain. 
After a detailed physicochemical characterization, the nanocomposites were evaluated 
in vitro and in vivo. Biocompatibility of the nanocarriers as well as the bioactivity of NGF 
were confirmed in rat pheochromocytoma (PC12) cells. The nanoparticles effectively 
induced neurite outgrowth without exhibiting significant cytotoxicity. Drug release was 
investigated using the dispersion releaser technology [26, 27] The transport of NGF 
into the brain was confirmed in vitro in bEnd3 cells. Finally, a combination of the 
nanocarriers with the small-molecular mitogen-activated protein kinase (MEK) inhibitor 
U0126 was tested in an in vivo model of stroke. U0126 protects the brain against 
ischemic brain damage and a synergistic effect was assumed [28, 29], 
2. Materials and methods 
2.1. Materials 
HSA, glutaraldehyde 25% aqueous solution, D-trehalose, saccharose, and mannitol 
were obtained from Sigma Aldrich (Munich, Germany). Nerve growth factor was 
supplied by Alomone Labs (Jerusalem, Israel). Apolipoprotein E3 was purchased from 
Peprotech (Hamburg, Germany). ATTO647N was purchased from ATTO-TEC GmbH 
(Siegen, Germany). 2-Iminothiolane HCL (Traut' s reagent) was obtained from Thermo 
Scientific (USA). Succinimidyl propionic acid PEG NHS (mPEG-SPA-5000) was given 
by NANOCS (USA). ɑ-Maleinimidohexanoic-ω-NHS PEG (MALHEX-NH-PEG-NHS) 
was manufactured by RAPP Polymere (Tübingen, Germany). Trypsinogen and 
proteinase K for the release experiments was purchased from Sigma Aldrich 
(Darmstadt, Germany).  
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2.2. Synthesis of Ce3/4+-cation-doped maghemite iron oxide 
particles 
The USPIO were synthesized using a nanofabrication method described previously 
[23]. In brief, FeCl3 • 6H2O (Fe3+ cations, 240.0 mg, 0.9 mmol) salt was dissolved in 
deoxygenated MilliQ water (4.5 mL) and mixed with a similar aqueous solution of 
FeCl2 • 4H2O (Fe2+ cations, 97.5 mg, 0.45 mmol, 4.5 mL H2O). This hybrid iron salt 
aqueous medium (N2 atmosphere) was first ultrasonicated (Bransonic® ultrasonic 
cleaner bath, 2510E MTH model, 42 KHz at full power) over a time period of 5 to 10 min 
at room temperature before introducing 24% of an aqueous NH4OH (0.75 mL) phase 
(one shot injection) causing an immediate black precipitation of corresponding 
magnetite (Fe3O4) nanoparticles. The procedure was followed by 19 additional minutes 
of ultra-sonication. Thus resulting Fe3O4 nanoparticles were transferred into a glass 
bottle (100 mL), magnetically decanted (with a strong external magnet), and washed 
with ddH2O (3 x 40 mL) until neutral pH was reached. The resulting black well-
dispersed magnetite nanoparticles were stored (30 mL nanoparticles suspension in 
ddH2O) before further processing. The ageing storage process was performed for a 
minimum of 2 h (room temperature) of storage time at room temperature. 
Afterwards, the former aqueous magnetite nanoparticles suspension (30 mL, 4.22 h 
ageing time) was magnetically decanted to separate magnetite nanoparticles from the 
aqueous phase. Cerium-containing inorganic CAN oxidant reagent 
[(NH4)2Ce(IV)(NO3)6], 500.0 mg, 0.912 mmol was dissolved in 6.0 mL of acetone and 
introduced to the decanted magnetite nanoparticles, followed by an addition of 18 mL 
of degassed MilliQ water. Finally, the corresponding multi-phase mixture was 
ultrasonicated using a high-power sonicator (Sonics®, Vibra cell, 750 Watt, power 
modulator set-up at 25%) - Titanium horn (0.5 h, 0°C - Inert argon atmosphere). 
2.3.  Preparation of theranostic core particles 
To prepare the theranostic core particle, an amount of 25 mg of HSA (fraction V, purity 
96–99%) was dissolved in 0.125 mL of MilliQ water and 0.25 ml of a dialysed NGF 
solution (1 mg/ml) was added. Afterwards, 10 µL of a 1 M sodium chloride solution and 
101 µL of a CAN-Fe2O3 suspension comprising 0.5 mg of iron were added. The pH 
was adjusted to 8.0 and the suspension was divided into 2 batches. To each batch, a 
total amount of 2 mL of ethanol 96% (v/v) was added using a peristaltic pump (Ismatec 
Laboratoriumstechnik GmbH, Wertheim, Germany) at a rate of 1.1 mL/min while 
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stirring the dispersion continuously at 400 rpm on a magnetic stirring plate. Finally, a 
stoichiometric amount of glutaraldehyde corresponding to the number of amino groups 
in the HSA molecule was added to crosslink the protein. Again, the particle suspension 
was continuously stirred for 4 hours. The nanoparticles were centrifuged using an 
Eppendorf centrifuge 5424 R (Eppendorf AG, Hamburg, Germany) at 20,000 rpm for 
25 min, washed trice and redispersed in MilliQ water or phosphate buffered saline 
(pH=7.4, PBS). 
2.4. Surface modification of theranostic core particles 
The surface of theranostic HSA nanoparticles was modified as described previously 
[11, 12]. For this purpose, the nanoparticles were activated using the bi-functional 
crosslinker MALHEX-NH-PEG-NHS. After thiolation of the ligand, ApoE was 
conjugated to the particle surface using the maleimide active group of the crosslinking 
agent.  
In brief, an amount of 20 mg of the theranostic core particles in 1.0 mL of PBS (pH 8.0) 
was mixed with 1.0 mL of PBS (pH 8.0) that contained a 10-fold molar excess of 
MALHEX-NH-PEG-NHS. The suspension was agitated for 1 hour (600 rpm, 20 ºC) in 
a thermomixer (Eppendorf AG, Hamburg, Germany). Afterwards, the suspension was 
dialysed against 250 ml MilliQ water for 2 hours and against 400.0 ml of 0.1 M NaHCO3 
buffer (pH 8.0) for 2 hours, respectively. In both cases, a dialysis membrane with a 
molecular weight cut-off (MWCO) of 10 kDa was used. 
The thiolation of ApoE was achieved by incubating 1.0 mg of the protein with a 50-fold 
molar excess of Traut's reagent in PBS over a time period of 2 hours at 600 rpm in a 
thermomixer (Eppendorf AG, Hamburg, Germany). Afterwards, ApoE was dialyzed 
against 200 ml MilliQ water using a membrane with 3.5 kDa MWCO for 2 hours and 
against 200.0 ml 0.1 M NaHCO3 buffer (pH 8.0) for 2 hours, respectively. 
Finally, the ApoE solution was incubated with the activated theranostic core particles 
for 18 h at 600 rpm and 20 ºC in a thermomixer system (Eppendorf AG, Hamburg, 
Germany). The resulting targeted theranostic particles were dialyzed against 500.0 ml 
of MilliQ water using a membrane with a MWCO of 100 kDa for 2 hours. 
For the cell-based in vitro assays, targeted theranostic nanocarriers were labelled 
using the amino-reactive fluorescent dye ATTO-647N. In this context, 0.5 mg of the 
nanoparticles in PBS (0.5 ml, pH 8.0) was mixed with 0.065 mL of an ATTO-647N 
solution in DMSO (0.1 mg/ml), and agitated for 50 min at 600 rpm and 20 ºC in a 
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thermomixer (Eppendorf AG, Hamburg, Germany). The nanoparticles were purified by 
repeated steps of centrifugation (25 min, 20,000 rpm, centrifuge 5424 R, Eppendorf 
AG, Hamburg, Germany) and redispersion in MilliQ water. 
As a control, HSA nanoparticles carrying PEG chains on their surface were prepared 
using the mono-functional crosslinking agent mPEG-SPA-5000 to the particle surface 
under similar conditions. 
2.5. Characterization of theranostic particles 
The morphology of targeted theranostic nanocarriers was investigated using a FEI 
Morgagni 268D transmission electron microscope (FEI, Hillsboro, USA). 
The particle size and size distribution were determined using the dynamic light 
scattering method with a Zetasizer Nano ZS (Malvern Instruments, Malvern, UK) 
equipped with a backscatter detector at an angle of 173°. The particles were 
characterized for the volume mean diameter and polydispersity index (PDI). 
2.6. Storage stability of theranostic particles 
To convert the targeted theranostic nanocarriers into a stable solid, form freeze-drying 
was applied. Mannitol, sucrose, and trehalose were evaluated as lyoprotectants at a 
concentration of 3% (w/v). For this purpose, a volume of 1.0 mL containing 10 mg/mL 
of targeted theranostic particles and a lyoprotectant was freeze-dried in a Christ 
Epsilon 2–7 freeze dryer (Martin Christ GmbH, Osterrode, Germany) as described 
previously [22, 30]. The physical stability of the targeted theranostic nanocarriers was 
investigated after 6 months of storage at 4 °C and reconstitution in the same volume 
of MilliQ water. The dynamic light scattering method was used to evaluate the size 
change due to the lyophilisation. 
2.7. Magnetization of theranostic nanocarriers 
The specific (mass dependant) magnetization of the freeze-dried targeted theranostic 
nanocarriers was determined using a superconducting quantum interference device 
(SQUID) magnetometer (Quantum Design Inc., San Diego, USA). The samples were 
fixed in a gelatine capsule and pulled through the induction coils (vibrating sample 
mode) of the magnetometer at constant temperature (300 K) and various constant 
external fields. 
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2.8. Determination of iron content of theranostic particles 
The iron content of the theranostic nanocarriers was quantified by inductively coupled 
plasma optical emission spectroscopy (ICP-OES) using a Spectro Genesis 
simultaneous spectrometer with axial plasma observation (Spectro Analytical 
Instruments GmbH, Kleve, Germany).  
Multi-elemental standard solutions for ICP calibration (Merck KGaA, Darmstadt, 
Germany) was used for calibration. The detection limit of iron was calculated according 
to equation 1:  
 
(1) 𝐿𝑖𝑚𝑖𝑡 𝑜𝑓 𝑑𝑒𝑡𝑒𝑐𝑡𝑖𝑜𝑛 =  𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝑠𝑖𝑔𝑛𝑎𝑙 + 3 ∗ 𝑆𝐷𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 ∗ 𝑓𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛  
 
A known amount of theranostic nanocarriers was dissolved in 5 M hydrochloric acid 
and diluted to be in the applied calibration range. 
2.9. Release from the HSA nanoparticle system using the 
dispersion releaser technology 
The release from HSA nanoparticles was determined using the dialysis-based 
dispersion releaser technology as described earlier by Janas et al. [26]. Since the 
testing requires relevant amounts of the protein, trypsinogen (molecular weight 24 kDa, 
isoelectric point 9.3) was selected as a model protein for NGF (molecular weight 26 
kDa, isoelectric point 9.3).  
For this purpose, the protein was labelled using a 3-fold molar excess of ATTO-647-
N-hydroxysuccinimde. Unbound fluorescent label was separated from labelled protein 
by using G-25 Sephadex size exclusion chromatography column (GE Healthcare Life 
Sciences, Buckinghamshire, UK). Subsequently diluted protein solutions obtained 
were concentrated by using Amicon Ultra centrifugal protein concentrators (Sigma 
Aldrich, Darmstadt, Germany). Desolvation and particle purification was carried as 
described in the section 2.3 above.  
The purified particles were redispersed in 1 ml of MilliQ water and a volume of 300 µl 
was introduced to the donor compartment. Acceptor medium for the release study was 
PBS. A semipermeable 100 kDa cellulose ester dialysis membrane was used to 
separate donor and acceptor compartment of the dispersion releaser. Volumes of 
500 µl were collected at predefined time points from the acceptor compartment. After 
6 hours, a small quantity (approximately 15 units of enzyme in 50 µl of volume) of 
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proteinase K solution was added to the donor compartment to change from a diffusion-
based to a degradation-based release mechanism [31].  
2.10. PC12 cytotoxicity and cellular bioactivity assay 
PC12 cells were cultured with Dulbecco's modified Eagle's medium containing 5% (v/v) 
fetal bovine serum (FBS), 10% (v/v) horse serum, and 1% (v/v) penicillin–streptomycin 
(37 °C, 5% CO2). The cytocompatibility of targeted theranostic nanocarriers was 
analysed using an 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide 
(MTT) assay in PC12 cells. Pre-cultured cells were seeded at a density of 5 × 104 per 
well in a 96-well plate and cultured for 24 h. An amount of 10, 25 and 50 g of targeted 
theranostic nanocarriers was added to each well in a volume of 5 l of PBS. The cells 
were incubated for 24 , 48, and 72 h. A volume of 20 l (10 % v/v) containing 5 mg/ml 
of MTT solution was added followed by incubation over 30 minutes. After removing the 
medium, the cells were lysed, and the absorbance of lysates was determined at 595 
nm using an EnVision 2104 multilabel reader (Perkin Elmer Inc., Waltham, USA). The 
percentage of viable cells was calculated in comparison to the untreated cells (control). 
 
In addition, the bioactivity of NGF via the outgrowth of neurites from PC12 cells to 
neural phenotype upon exposure to NGF was investigated. The PC12 cell 
differentiation assay has been applied to test the activity of NGF earlier (Johnson et al. 
2008). The cells grow neurites when exposed to NGF at concentration higher than 
approximately 10 ng/mL [32]. For this purpose, 5 × 104 cells per well were seeded in 
24-well plates. NGF solution in PBS containing residues of poly ethylene glycol, HSA 
nanoparticles without NGF and PBS solution were used as controls. All reference 
samples containing NGF were studied with the following NGF at concentrations of 6.25 
ng/ml, 12.5 ng/ml, 25 ng/ml, 50 ng/ml, 100 ng/ml, 500 ng/ml, 1000 ng/mL. Neurite 
outgrowth was examined and imaged by phase-contrast microscopy, and 
representative cells were photographed with a CCD camera (Zeiss, Oberkochen, 
Germany) after 3 days of exposure to the nanocarriers or pure growth factor. 
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2.11. Transport studies of theranostic nanoparticles using an in vitro 
BBB model 
 
A number of 10,000 bEND3 cells were seeded in a 100 µl culture medium on 24 well 
1 µm ThinCerts which were precoated with 100 µl FBS for 30 min. In the lower 
compartment (basolateral), 1 ml of culture medium, 10% FBS (heat inactivated), L-
glutamine and Na-pyruvate was added. As a control, half of the ThinCerts were not 
seeded with cells. ThinCerts with and without cells were incubated in the laminar flow 
bench at room temperature for one hour (to allow cells settling down) and subsequently 
for two hours at 37°C. Afterwards, they were transferred to the cellZscope2 
(nanoAnalytics, Münster, Germany). Two hundred microliters of medium were added 
to the ThinCerts to reach a final volume of 300 µl in the upper compartment (apical). 
The transendothelial electrical resistance (TER) and capacitance were measured 
every hour for 5 days. After 5 days the medium was changed to DMEM with 2 % FBS, 
2 mM L-glutamine, Na-pyruvate and 110 nM hydrocortisone. Hydrocortisone was 
added to increase and to stabilize the TER value. The TER and capacitance values 
were measured every hour for 1 day. A volume of 17 µl of the theranostic targeted 
nanoparticles, as well as the PEGylated reference formulation (without ApoE coating) 
were added to the cells (apical). The TER and capacitance values were recorded every 
30 minutes for one day. A volume of 200 µl of the nanoparticle samples (basolateral) 
were transferred to a black 96 well plate and measured in a plate reader using an 
excitation wavelength of 646 nm and an emission wavelength of 664 nm (ENSPIRE® 
Multimode plate reader, Perkin Elmer,Waltham, USA). 
2.12. Ethics 
All experiments were carried out in strict accordance with the guidelines for the 
European Community Council directive (2010/63/EU) for protection of vertebrate 
animals used for experimental and other scientific purposes. The surgeries were 
approved by Lund County Administrative Court under the auspices of the Swedish 
Department of Agriculture (M188-12). The study complies with the ARRIVE guidelines 
(Animal Research: Reporting In Vivo Experiments). 
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2.13. Animals and treatments 
Male Wistar rats obtained from Janvier were used for the experiments. Transient 
middle cerebral artery occlusion (tMCAO) model was induced for 2 hours followed by 
reperfusion. All animals were randomly divided into 3 groups; (i) vehicle treated, (ii) 
treated with U0126 and (iii) treated with NGF in combination with U0126.  The MEK1/2 
inhibitor U0126 was given at 0 and 24 h post reperfusion and NGF was given at day 3 
post-stroke. Animals were randomly selected for treatment that was blinded to the 
operator.  
2.14. Transient middle cerebral artery occlusion model 
The experimental stroke model was performed by using an intraluminal filament 
technique [33] to induce transient middle cerebral artery occlusion in male Wistar rats. 
Anesthesia was induced by 3.5% isoflurane in N2O:O2 (70:30) and then maintained by 
inhalation of 1.5-2% isoflurane in N2O:O2 (70:30) during the surgical procedure. The 
measurement of blood pressure, pH, pCO2, pO2 and blood glucose was performed 
prior to the occlusion. To maintain body temperature during the surgical procedure a 
rectal temperature probe connected to a homoeothermic blanket was used. An incision 
was made in the midline of the neck, and the right common, internal and external 
carotid arteries were exposed. The right common and external carotid arteries were 
ligated permanently with sutures. A silicon rubber-coated monofilament (Doccol 
Corporation, Sharon,  USA) was inserted into the right internal carotid artery and further 
advanced until the tip of the filament reached the entrance of the middle cerebral artery. 
The resulting occlusion was confirmed by Laser-Doppler flowmetry. Average Laser-
Doppler flow reductions of cerebral blood flow were 71± 2%. Following insertion of the 
filament the rats were sewed and regained consciousness. Two hours after occlusion, 
the rats were re-anesthetized and the filament removed to achieve reperfusion as 
verified by Laser-Doppler flowmetry. At the end of the surgery, the rats received a 
subcutaneous injection of 10 ml of isotonic saline for hydration.  
2.15. Pre-clinical MR imaging at 9.4T to evaluate infarct volume 
MRI monitoring was performed at day 14 post-stroke on a 9.4 T preclinical MRI 
horizontal bore scanner (Biospec Bruker,Billerica, USA) in conjunction with the 
205/120 HD gradient coil unit. During the imaging procedure, the breathing rate and 
body temperature were monitored.  The imaging was performed accordingly to 
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previous described protocols [29]. The 1H T2-weighted images were acquired to 
measure the infarct volume. Images were analyzed using a self-written script in 
Matlab® (Natick, Massachusetts, USA). The region of interest (ROI) corresponding to 
the whole ischemic lesion was manually delineated by an operator blinded to the 
treatment group and the extension of damage was reported as infarct volume (mm3). 
 
2.16. Statistics 
All outcomes were expressed as the mean value ± standard deviation (SD). The 
experiments (except the preformulation studies) were performed in triplicate at least 
(single experiments are indicated in the figure legend). The mean value and SD were 
analyzed by using Microsoft Excel (Microsoft, Redmond, USA). Particle 
characterization data was analyzed and illustrated using SigmaPlot 17.0 (Systat 
Software GmbH, Germany). Statistical significance of various processes on particle 
size and in vivo experiments was analyzed using a one-way ANOVA test. Where 
indicated different statistical tests were used. 
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3. Results 
Theranostic NGF-loaded nanocarriers were manufactured by embedding USPIO and 
NGF into HSA core particles followed by surface modification with ApoE. The release 
of NGF was investigated with the help of the dispersion releaser technology [26]. The 
nanocarriers were evaluated for NGF bioactivity and cytotoxicity in PC12 cells and the 
transport through the BBB was studied in vitro using bEnd3 cells. The effect of a 
combination treatment of NGF with the small-molecular MEK inhibitor U0126 was 
studied in an animal model of stroke. 
3.1. Preparation of advanced NGF-loaded theranostic nanocarriers 
The diagnostic MRI-enabling maghemite (-Fe2O3)-based iron oxide particles were 
synthesized by two consecutive nanofabrication steps, the preparation of ultra-small 
basic Massart magnetite (Fe3O4) nanoparticles followed by an optimized surface 
engineering method as described previously [23]. The nanoparticles were 
characterized for size by transmission electron microscopy (TEM) (6.61 ± 2.04) and by 
DLS (60 ± 2 nm, 0.136) as presented in Figure 1. It should be noted that, the 
hydrodynamic diameter measured by DLS is systemically larger than the one observed 
in TEM micrographs [34]. 
 
Figure 1: Standard (A) and high-resolution (B) transmission electron micrograph, selected diffraction (SAED) 
pattern (C) and size distribution histogram (D) of ultra-small 6.61±2.04 nm-sized USPIO. 
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A zeta potential value of +45.7 ± 1.88 mV together with a Ce/Fe ratio of 0.1000 was 
obtained. To encapsulate USPIO into albumin nanocarriers, the desolvation method 
was applied [35]. Presumably both, a positive surface charge and Ce3/4+ cations 
coordinative linkage led to a strong interaction with the negatively charged matrix 
material [22].  
 
In previous designs, the HSA-CAN maghemite hybrid particles were optimized with an 
average diameter of 170 ± 10 nm [21]. However, particle size differed significantly, 
when NGF was present. When adjusting an initial iron content of 1 % (m/m) a particle 
size between 141 ± 1 nm (pH 6.5) and 207 ± 1 nm (pH 8.5) was obtained (see Figure 
2, left). Elevated pH values resulted in a considerable reduction of the particle yield, 
which was even more pronounced in presence of sodium chloride. Therefore, 
nanoparticle synthesis was conducted in absence in sodium chloride 
 
Finally, theranostic nanocarriers were synthesized at a pH of 8.0. The HSA 
nanoparticles exhibited a hydrodynamic diameter of 152 ± 6 nm (PDI 0.037 ± 0.009) 
and a particle yield of 75.3 ± 4.9 % yield (m/m). A zeta potential of -47.7 ± 1.4 mV 
indicated high physical stability of the dispersion. In presence of NGF, a particle 
diameter of 191 ± 2 nm (PDI 0.021 ± 0.017) with a particle yield of 71.5 % (m/m) and 
a zeta potential of -48.3 mV was obtained.  
 
Figure 2: Particle size, particle yield, and polydispersity index of nanoparticles in the preformulation studies (left) 
synthesized at different pH values (particle size: light green bar, particle yield: dark green bar, PDI: white dot) (n=1). 
Particle size and polydispersity index of nanoparticles (right) before (particle size: light green bar, PDI: white dot) 
and after (particle size: dark green bar, PDI: white triangle) lyophilisation using mannitol, sucrose or trehalose as a 
lyoprotector (n=3, mean  ± SD). 
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The conjugation with ApoE resulted in a slight but not significant (ANOVA) increase in 
particle size to 212 ± 1 nm (PDI 0.075 ± 0.022).  
 
Morphology of the targeted theranostic nanocarriers was explored by TEM. As 
expected, USPIO were embedded into the spherical cross-linked matrix system 
comprising HSA and NGF (see Figure 3). Finally, the magnetization of the theranostic 
nanocarriers, that contained 1.6 % (w/w) and 4.6 % (w/w) iron, was examined using a 
SQUID magnetometer. Converting the iron content to 100 % of CAN-maghemite the 
resulting saturation magnetization values (53.0 emu/g and 54.1 emu/g) were 
comparable to those of CAN-maghemite (59.5 emu/g).  
 
 
 
Figure 3: Transmission electron micrograph of targeted theranostic nanocarriers at 10000-fold (A) and 20,000-fold 
(B) magnification. 
3.2. Storage stability or nanosuspensions after freeze drying 
The initial formulation studies revealed a lyoprotector concentration of 3% as beneficial 
for the lyophilisation process. Therefore, the hybrid particles were freeze-dried in 
presence of 3% (w/v) mannitol, sucrose and trehalose at a nanoparticle concentration 
of 10 mg/ml and tested for their physical stability after 6 months of storage at 4 °C and 
redispersion in MilliQ water. In the presence of sucrose and trehalose, the stability was 
maintained as indicated by particle size and PDI (see Figure 2, right). However, in the 
presence of mannitol, the particle size and PDI were considerably increased. 
Therefore, for further studies, all preparations were freeze-dried in the presence of 
sucrose.  
3.3. In vitro characterization of theranostic nanocarrier formulations 
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To exclude acute toxicity of the novel albumin-based targeted nanocomposites, the 
biocompatibility was tested. Cell viability was compared to a reference of untreated 
cells after an incubation time of 24, 48 and 72 h (see Figure 4).  
 
Figure 4: Cell viability of PC12 cells treated with 100 ng, 250 ng and 500 ng of NGF as well as 10 µg, 25 µg, and 
50 µg of NGF-loaded nanoparticles after 24, 48 and 72 h of incubation. The viable cell mass was measured by the 
MTT assay. (n=4, mean ± SD). 
 
This investigation was complemented by an evaluation of the bioactivity of NGF after 
encapsulation into the nanocarrier system. After several steps of processing including 
desolvation, chemical crosslinking, the surface modification, and lyophilisation, an 
influence on the bioactivity of the growth factor was assumed. The capacity of PC12 
cells for neurite outgrowth has been used this way earlier [32]. 
 
Interestingly, the surface modification of NGF with polyethylene glycol (PEG) 
contributed to an enhanced stability of the protein [32] (see Figure 5D). The processing 
of NGF resulted in a substantial loss of biological activity. Neurite outgrowth was 
observed at more than an order of magnitude higher theoretical NGF concentration 
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(500 ng/ml, see Figure 5 F) in comparison to NGF solution or lyophilised and 
reconstituted NGF (12.5 ng/ml, see Figure 5 B,D). 
 
To investigate the reasons behind the reduced activity, a drug release study was 
conducted using the dispersion releaser technology [26]. Compared to other methods, 
the dialysis-based setup allows a highly sensitive and reproducible measurement even 
in presence of serum proteins and other biorelevant media [27, 36]. The total drug 
release remained below 20% during the first 4 hours reaching a maximum value of 
17.98 ± 17.82%. After 6 hours, proteinase K was added to the donor compartment in 
order to change the mechanism of release from diffusion to  
degradation [31]. As a result, release increased to 32.4 ± 10.3%. 
 
 
Figure 5: In vitro neurite outgrowth of rat embryonic pheochromocytoma cells (PC12) after incubation with NGF-
PEG solution (A: 6.25 ng NGF/well, B: 12.5 ng NGF/well), NGF-PEG lyophilisate solution (C: 6.25 ng NGF/well, D: 
12.5 ng NGF/well), HSA-CAN maghemite-NGF-ApoE nanocomposite (E: 100 ng NGF/well, F: 500 ng NGF/well) 
and blank HSA-CAN maghemite nanocomposite (Control: 50 µg). 
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To complement these studies, the transport of nanocarrier formulations through an 
artificial BBB was investigated in vitro. For this purpose, a transwell assay system was 
applied using a confluent cell layer of the bEnd3 cell line. The TER value was 
monitored over the time of the experiment. A similar model has been used earlier to 
confirm the nanocarrier-mediated uptake of drugs into the brain [37]. After 48 h of 
incubation, the NGF concentration (measured as fluorescence intensity) was 
significantly higher in the basolateral compartment compared to the reference 
formulation without ApoE (see Figure 6A). 
 
Figure 6: The penetration potential of nanocarriers was measured by detecting the fluorescence level in the 
basolateral compartment after 0 h and 48 h. ApoE-coated nanocarriers show an increased penetration in 
comparison to PEGylated nanocarriers (control). *** p<0.001 indicates significant difference between ApoE-coated 
and PEGylated nanocarriers (t-test). B) To quantify changes of the TER, TER value 20 h after addition of the 
formulation (vehicle, ApoE-coated nanocarriers, PEGylated nanocarriers) was related to the TER value before the 
addition of the nanocarrier. The PEGylated nanocarriers reduce the TER value in comparison to the vehicle-treated 
control. ***p<0.001 indicates significant difference between nanocarrier treated samples and vehicle treated 
samples (Bonferroni's multiple comparisons test). 
The constant TER value indicated an intact barrier (see Figure 6B), however, there 
were some minor effects of the reference formulation on barrier integrity observed (see 
Figure 6B). This was not the case for the ApoE coated particles (see Figure 6B). 
 
3.4. Brain recovery after stroke 
Brain recovery after stroke was investigated inducing transient middle cerebral artery 
occlusion in male Wistar rats as described previously [33]. The brain infarct volume 
was determined from T2-weighted magnetic resonance images on day 14 post-stroke 
(see Figure 7A-C). A vehicle-control (see Figure 7A,D), the small molecule MEK 
inhibitor U0126 (see Figure 7D) and a combination of U0126 together with the NGF-
loaded drug delivery system were tested (see Figure 7C,D). 
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Figure 7: MR images of infarct site as well as the evaluation of infarct volume post-administration of vehicle control 
(A,D), U126 (B, D), and NGF-loaded nanocarriers in combination with U0126 (C, D) 14 days after stroke. (n=9, 
mean ± SEM); * indicates significant differences between treatment and vehicle treated rats (ANOVA, p<0.05). 
(Kruskal-Wallis test with Dunn’s multiple comparisons analysis) 
For the combination treatment using NGF-loaded theranostic nanocarriers and U0126, 
significant reduction of the infarct size was observed compared to the vehicle control 
(see Figure 7). U0126 alone also showed a significant reduction of the infarct size, 
however, there was no significant difference between the two treatments observed 
(see Figure 77). 
4. Discussion 
Today, stroke is a leading cause of death globally and is responsible for 9% of all 
deaths around the world [2]. A family of neurotrophins including NGF is involved in 
cerebral recovery [38] and was studied as a therapeutic option for brain injury [7]. 
Moreover, inhibition of MEK, a pathway which is activated following cerebral ischemia 
[39-42], in the acute phase of stroke, can improve the long-term neurological outcome 
[29, 43].  
 
Unfortunately, NGF is not able to pass the BBB which effectively controls the cellular 
and molecular traffic between the brain and the periphery [8, 44]. To bypass this 
barrier, previous studies utilized infusion into cerebral ventricles leading to a significant 
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reduction of delayed neuronal death in rats [3]. In a clinical setting, there were two 
cases of infants reported where the intraventricular administration of NGF showed a 
beneficial effect on recovery of hypoxic-ischemic brain injuries and cerebral perfusion 
[4, 5]. 
 
Over the years, a broad array of methods has been developed to enhance access of 
drugs to the brain at therapeutically meaningful concentrations [6, 7]. Nanocarrier 
delivery turned out to be an alternative to the conventional interventions. PBCA 
nanoparticles coated with polysorbate 80 were successfully used to deliver NGF to the 
brain after intravenous injection [13]. The adsorption of apolipoproteins followed by 
active transport through the BBB are the most likely mechanism [14]. Animals treated 
with the drug delivery system exhibited improved recognition and memory in the 
passive avoidance reflex (PAR) test [13]. 
 
In another study, transcytosis of targeted HSA nanoparticles through the brain 
endothelial cells was confirmed in vitro [15] and in vivo [12]. These particles were 
modified on their surface with ApoE [12, 15]. Even the short half-life of HSA 
nanoparticles in blood plasma [45] allowed the delivery system to access all six 
investigated brain regions [12]. 
 
In the present approach, nanocarriers for the treatment of stroke comprising a 
biodegradable matrix of HSA and NGF were modified on their surface with ApoE in 
order to deliver the growth factor to the brain. Further, USPIO were embedded into 
these nanoparticles to introduce diagnostic functionality to the delivery system. With 
an average diameter of 212 ± 1 nm (PDI 0.075 +/- 0.022), the nanoparticles were in a 
similar size range compared to earlier studies (200-250 nm) [12]. A monodisperse size 
distribution and optimal storage stability were achieved after freeze drying. As reported 
earlier, sucrose turned out to be an efficient lyoprotector for protein particles (see 
Figure 2, right) and was used to convert the liquid into a solid dispersion [30].  
 
To track the in vivo biodistribution during later stages of preclinical and clinical 
translation, USPIO were co-encapsulated into the particle matrix. Initially, CAN 
maghemite particles were characterized for their particle size and size distribution (see 
section 3.1). As previously reported, the hydrodynamic diameter of USPIO (measured 
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by DLS) was significantly larger compared to the one determined by electron 
microscopy [34].  
 
Afterwards, successful encapsulation into the protein structure was visualized by TEM 
(see Figure 3). USPIO were homogeneously distributed and saturation magnetization 
values were comparable to the non-encapsulated suspension. The iron load was even 
higher compared to current literature [21]. Against this background, the particles might 
be suitable for MRI applications as required to explore biodistribution patterns [21]. 
 
As a next step, the toxicity and bioactivity of NGF-loaded nanocarriers was determined 
in vitro. After three days of incubation, the neurotrophin as well as the NGF-loaded 
nanocarriers induced neurite outgrowth in PC12 cells [32] suggesting that NGF 
remained active through the encapsulation procedure and was released from the 
carrier. Compared to NGF, the extent of this outgrowth was lowered for the 
nanoparticles (see Figure 5). The assay provides only semiquantitative information and 
more efforts will be made to study structure-activity relationships of the nanosystem. A 
delayed release of NGF from the carrier as well as a lowered activity following the 
processing and chemical modification of the protein can be assumed.  
 
The in vitro release was studied using the dispersion releaser technology [26]. It 
remained below 20% during the first 4 hours (17.98 ± 17.82%). However, there was 
also a high variability observed between the three vessels which was in line with the 
rather complex release mechanism assumed for the carrier. With a molecular weight 
of approximately 24 kDa the utilized model protein (trypsinogen) presumably had 
multiple interactions with the particle surface and pore structure of the nanocarrier 
which can lead to altered release patterns. After 6 hours, the release mechanism was 
shifted to a degradation-based release by adding proteinase K to the donor 
compartment. Degradation of HSA nanoparticles in presence of the enzyme has been 
studied previously [31]. A maximum release of 32.41 ± 10.35% was achieved. The 
results confirm the outcome of the bioactivity assay showing a lowered activity but also 
explain the difficulties of applying in vitro findings to the in vivo situation. Further 
investigations of drug release as well as an optimization of the formulation parameters 
may be necessary. 
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A number of studies suggested the delivery of NGF after transcytosis of the ApoE-
coated nanoparticles through the BBB [11, 12, 15]. The LRP1 receptor was held 
responsible for this uptake [15]. In the present investigation, the transport of 
nanocarriers was investigated in vitro using a transwell assay system and bEnd3 cells 
[37]. After 48 h the NGF concentration was significantly higher in the basolateral 
compartment for the ApoE-coated particles compared to the reference formulation (see 
Figure 6A). The TER value was slightly lowered for the control, indicating an influence 
of the reference on the barrier properties (see Figure 6B). Generally speaking, there 
are more advanced models of the BBB necessary, to detect the influence of slight 
formulation changes on drug transport [15]. For the ApoE-coated nanocarrier 
formulation a TER value of 79.81 ± 8.58 Ω.cm2 was found. For comparison, in the in 
vivo setting, a TER value of 5900 Ω.cm2 has been detected. More recent cell-based 
models of the BBB achieve TER values of more than 500 Ω.cm2 [46]. However, using 
this model a transport mechanism was confirmed which has been reported for ApoE-
coated particles in a number of studies [15, 47, 48]. 
 
Finally, the efficacy of NGF-loaded nanocarriers was tested in combination with the 
small molecular MEK inhibitor U0126 in the transient middle cerebral artery occlusion 
in male Wistar rats [33]. The infarct size was significantly reduced compared to the 
vehicle control for the combination therapy as well as for U0126 alone.  
Unfortunately, there was only a slight but not significant difference observed in the 
infarct size between the two therapies (combination and U0126 alone), presumably 
due to the small group size (see Figure 77). However, this trend was confirmed by the 
neurologic examination following the well-established 6-point and 28-point scoring 
systems [49-51] (Data not shown). This clearly suggests the effective delivery of NGF 
to the brain as well as a synergistic effect of the neuropeptide with the MEK inhibitor. 
The outcome of the neurologic examination and the histological evaluation will be 
published in a separate manuscript (Ansar et al. 2018, Manuscript in preparation). 
Further research will investigate the biodistribution of these theranostic nanocarriers 
using their superparamagnetic properties. Additionally, the therapeutic effect of NGF-
loaded nanocarriers will be tested alone to learn more about the mechanisms 
underlying this synergistic neuroprotection. 
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5. Conclusions 
The presence of the BBB poses an obstacle to drug delivery. Over the years, 
ways have been discovered to address specific transport mechanisms on the surface 
of the brain endothelial cells allowing therapeutics to enter the CNS. In the present 
study, we successfully encapsulated NGF and USPIO into an albumin matrix. These 
nanocomposites with a size of approximately 200 nm attained their superparamagnetic 
properties and exhibited low toxicity. After modification of the particle surface with 
ApoE, the particles were able to cross an artificial BBB and remained bioactive in terms 
of the regulation of neurite outgrowth. In an animal model of stroke, a slight reduction 
of the infarct volume indicated a synergistic therapeutic effect of NGF and the small-
molecular MEK inhibitor U0126. The trend was also confirmed by an in-depth 
investigation of the neuroscore that will be published by Ansar and co-workers 
(manuscript in preparation). Further research will be necessary to study the 
biodistribution of this nanocarrier system as well as to understand the mechanisms 
underlying these observations. 
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